Products Porfolio &
LAI Opportunities
Fast expending portfolio
Already 4 programs in Preclinical & Clinical
Our pipeline
LEAD FORMULATION RESEARCH
| mdc-WWM CONTRACEPTION PARTNER: BILL & MELINDA GATES FOUNDATION | mdc-ANG CNS* PARTNERED |
| mdc-ELK DEPRESSION | mdc-NVA PAIN |
| mdc-GRT ORGAN TRANSPLANT | mdc-DOM UROLOGY |
PRECLINICAL & CLINICAL DEVELOPMENT
Favorable risk assessment
All current products under development are based on already approved APIs. When compared to NCEs (New Chemical Entity), use of well-understood, approved APIs is an opportunity to make treatments quickly available with significantly less financial resources needed and less risk in clinical phases.
LAI Opportunities
Identification
We have designed a strong procedure to identify LAI opportunities and enlarge our portfolio of proprietary and partnered products. This assessment process aims to identify the unmet needs in a large panel of indications that could be met with LAI and to identify the most compatible APIs with our technology. This preliminary step is essential to increase significantly the likelihood of success for each product entering formulation stage.
Opportunities
with approved APIs
Products based on already approved APIs can benefit from decreased time-to-market thanks to simplified pathways such as the 505(b)2 in the US, while providing all of the benefits from long-acting formulations with controlled release.
Opportunities
with new APIs
There are a fair amount of new therapeutic molecules that could be optimized for long-acting injectable treatments. Our technology could be the empowering entity to APIs that can’t be used in today’s traditional, drug delivery systems, or whose benefits would be limited as a result of toxicity.
We’re always looking for new talent